Author's reply to criticism of study on benzodiazepines and risk of hip fracture

doi:10.1136/bmj.323.7315.752/a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Nicholas Moore (nicholas.moore@pharmaco.u-bordeaux2.fr), professor of clinical pharmacology

Université Victor segalen-Bordeaux2, Bordeaux, France

EDITOR—Sgadari et al's letter1 commented on the study that I and several others carried out to see whether benzodiazepines are associated with an increased risk of hip fracture.2 We found that they are not.

In their large case-control study of 9752 patients with hip fractures compared with 38 564 controls, …